Cipher Pharmaceuticals (CPH) Competitors

Cipher Pharmaceuticals (TSE:CPH) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Does the media prefer CPH or CRON?

In the previous week, Cipher Pharmaceuticals had 7 more articles in the media than Cronos Group. MarketBeat recorded 7 mentions for Cipher Pharmaceuticals and 0 mentions for Cronos Group. Cipher Pharmaceuticals' average media sentiment score of 0.87 beat Cronos Group's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Positive
Cronos Group	Neutral

Which has preferable valuation and earnings, CPH or CRON?

Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$47.59M	7.75	C$11.41M	C$0.46	31.57
Cronos Group	C$130.28M	10.11	-C$32.78M	C$0.05	68.80

Do insiders & institutionals hold more shares of CPH or CRON?

3.2% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Cronos Group shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Comparatively, 46.4% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts prefer CPH or CRON?

Cipher Pharmaceuticals currently has a consensus target price of C$14.75, indicating a potential upside of 1.58%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Cipher Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility and risk, CPH or CRON?

Cipher Pharmaceuticals has a beta of 0.774739, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.299122, indicating that its share price is 30% more volatile than the S&P 500.

Is CPH or CRON more profitable?

Cipher Pharmaceuticals has a net margin of 59.92% compared to Cronos Group's net margin of -42.65%. Cipher Pharmaceuticals' return on equity of 17.93% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	59.92%	17.93%	7.90%
Cronos Group	-42.65%	-4.40%	-3.73%

Summary

Cipher Pharmaceuticals beats Cronos Group on 9 of the 15 factors compared between the two stocks.